Erosive hand osteoarthritis (OA) of the interphalangeal (IP) joints is characterised by a more pronounced inflammatory burden of disease.1 Whether it is a subset of hand OA or just a radiographic phase remains a matter of debate. The pathogenesis of erosive OA is not yet understood, but articular cartilage degeneration and subchondral bone resorption are some of the major characteristics. In general, several cytokine-driven pathways such as receptor activator of nuclear factor κB, interleukin-1 and tumour necrosis factor (TNF) alpha are involved at the level of the subchondral bone-inducing dynamic morphological changes.2–4 In post hoc analyses in two recent placebo-controlled pilot studies in erosive OA, it was shown that adalimumab and etanercept were able to diminish structural progression after 1 year of treatment in a subgroup of patients who showed soft tissue swelling at baseline.5 ,6 We hypothesised …

中文翻译：

---

放射性标记的 certolizumab pegol 对侵蚀性手骨关节炎患者肿瘤坏死因子的免疫闪烁扫描检测：一项概念验证研究

指间 (IP) 关节的侵蚀性手部骨关节炎 (OA) 的特点是疾病的炎症负担更明显。1 它是手部 OA 的一个子集还是只是放射学阶段仍然存在争议。侵蚀性 OA 的发病机制尚不清楚，但关节软骨退变和软骨下骨吸收是一些主要特征。一般而言，在软骨下骨诱导动态形态变化的水平上涉及多种细胞因子驱动的途径，例如核因子 κB 的受体激活剂、白细胞介素-1 和肿瘤坏死因子 (TNF) α。 2-4 在事后分析中在最近两项针对侵蚀性 OA 的安慰剂对照试验研究中，